Deep Bio
Deep Bio Presents Research Results of AI-based Cancer Diagnosis and Prognosis at the AACR Annual Meeting 2022
Deep Bio Presents Research Results of AI-based Cancer Diagnosis and Prognosis at the AACR Annual Meeting 2022 Five abstracts in prostate and breast cancers, Deep Bio’s main research areas, are present...
DeepBio’s AI-based prostate cancer pathology diagnosis wins new tech certification
DeepBio has announced that its deep learning-based prostate cancer pathology diagnosis technology using a Gleason grading system acquired NET (new excellent technology) certification on Tuesday...
Regulator OKs DeepBio’s AI-based Prostate Cancer Pathology Diagnosis SW
DeepBio said its DeepDx-Prostate Pro, an artificial intelligence (AI)-based pathology diagnosis assistance software, has received a Class 3 in-vitro diagnostic medical device from the Ministry of Food...
Gestalt Diagnostics and Deep Bio Announce Strategic Relationship to Deliver Image Analysis Algorithms within Gestalt’s Digital Pathology Platform
SPOKANE, Wash. and SEOUL, South Korea, July 14, 2021 /PRNewswire/ — Gestalt Diagnostics and Deep Bio today announced their strategic relationship on the development of an integrated workflow for...